Xenograft‐Derived Cell‐Free Deoxyribonucleic Acid as an Early Biomarker of Rejection in Genetically Engineered Pig‐to‐Non‐Human Primate Kidney Xenotransplantation
Xenotransplantation · 2025
DOI: 10.1111/xen.70100 ↗Kurz gefasst
Fachartikel in der Zeitschrift Xenotransplantation, 2025. Verfasst von Kyu-Hyun Han und 14 weiteren Autor:innen. Beteiligte Einrichtung: The Research Institute For Transplantation, Yonsei University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Graft Rejection, Kidney Transplantation, Transplantation, Heterologous, Heterografts. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare.
Abstract (Originalsprache)
Introduction
Non‐invasive biomarkers that detect xenograft injury before irreversible damage are essential for improving kidney xenotransplantation outcomes. This study investigated whether xenograft‐derived cell‐free DNA (xdcfDNA) is helpful as a non‐invasive, early biomarker of antibody‐mediated rejection.
Methods
Kidneys from genetically engineered pigs (GGTA1/CMAH/iGb3s/B4GalNT2 knockout; CD39, CD55, CD46, TBM knock‐in) were transplanted into 10 cynomolgus monkeys, which received thymoglobulin, rituximab, anti‐CD154 monoclonal antibody, corticosteroid, tacrolimus, and mycophenolate mofetil. Plasma xdcfDNA was measured using species‐specific quantitative polymerase chain reaction. Pathological scoring and rejection diagnosis of the kidney xenograft biopsy were performed based on the Banff 2022 criteria.
Results
XdcfDNA levels increased markedly before an overt increase in serum levels of creatinine and blood urea nitrogen after kidney xenotransplantation. When recipients were classified into low‐ and high‐score groups based on the Banff score of kidney xenograft biopsy, xdcfDNA levels were higher in the high‐score groups for intimal arteritis (v), composite vasculitis (g + ptc + v), tubular atrophy (ct), interstitial fibrosis (ci), and IgG deposition. Furthermore, the rejection group showed higher xdcfDNA levels than the non‐rejection group ( p = 0.0270). The cut‐off xdcfDNA value for xenograft rejection was 2.545%, with an apparent sensitivity of 100% (95% confidence interval, 64.57%–100.00%) and specificity of 100% (43.85%–100.00%).
Conclusions
XdcfDNA is a potentially sensitive, noninvasive, and early biomarker of xenograft rejection, capturing vasculitis and subsequent chronic injury. Periodic monitoring of xdcfDNA could support noninvasive screening of rejection before overt functional changes in xenografts emerge and might contribute to guiding confirmatory xenograft biopsy and subsequent immunosuppression modification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Research Institute For Transplantation, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Department of Surgery, Konkuk University School of Medicine, Seoul, Republic of Korea.
- Institute For Experiments of Non-clinical NHP Solid Organ Xenotransplantation, Konkuk University School of Medicine, Seoul, Republic of Korea.
- Graduate School of Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Förderung
- Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare
Zitieren
APA
Han, K. H., Jang, J. Y., Jung, M., Hwang, S. A., Yun, I. H., Lee, H., Seong, M., Kim, B., Jeong, J. C., Hwang, J. H., Min, S., Kim, H., Kim, B. S., Yun, I. J., & Yang, J. (2025). Xenograft‐Derived Cell‐Free Deoxyribonucleic Acid as an Early Biomarker of Rejection in Genetically Engineered Pig‐to‐Non‐Human Primate Kidney Xenotransplantation. Xenotransplantation. https://doi.org/10.1111/xen.70100
Vancouver
Han KH, Jang JY, Jung M, Hwang SA, Yun IH, Lee H, et al. Xenograft‐Derived Cell‐Free Deoxyribonucleic Acid as an Early Biomarker of Rejection in Genetically Engineered Pig‐to‐Non‐Human Primate Kidney Xenotransplantation. Xenotransplantation. 2025. doi:10.1111/xen.70100
BibTeX
@article{Han2025,
author = {Han, Kyu-Hyun and Jang, Joon Young and Jung, Minsun and Hwang, Sun Ae and Yun, Il Hee and Lee, Hwan and Seong, Minhee and Kim, Bomin and Jeong, Jong Cheol and Hwang, Jeong Ho and Min, Sangil and Kim, Hyunil and Kim, Beom Seok and Yun, Ik Jin and Yang, Jaeseok},
title = {Xenograft‐Derived Cell‐Free Deoxyribonucleic Acid as an Early Biomarker of Rejection in Genetically Engineered Pig‐to‐Non‐Human Primate Kidney Xenotransplantation},
journal = {Xenotransplantation},
year = {2025},
doi = {10.1111/xen.70100}
}
EUVIMED